An Open, Randomized, Parallel-group, Multicenter Clinical Study to Evaluate Efficacy and Safety of Paclitaxel Every 2 Weeks Compared Weekly in Adjuvant Treatment of Breast Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin
- Indications Breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms PATEN
- 14 May 2013 New trial record
- 07 May 2013 Biomarkers information updated